Loading...

VILINBIO Vilin Bio Med Ltd Other Situations Announcement

Vln

VLNB

Vilin Bio Med Ltd

(VILINBIO)

2025 Announcement

Show Summary

Show Summary

Funds Utilisation Update

Suspension Revoked

Disclosure Submission

Financial Results Submitted

Regulatory Update

Public Announcement

Open Offer Announcement

Database Compliance

Compliance Certificate

Compliance Report Filed

General Updates

General Updates

Corrigendum Submission

Material Issue Disclosure

Material Issue Disclosure

Open Offer Announcement

Trading Window Closure

Open Offer Announcement

NSE Fine Update

Board Meeting Outcomes

Board Meeting Outcomes

Compliance Confirmation

Compliance Certificate

Board Meeting Update

Debt Disclosure

Director Resignation

Financial Disclosure

Financial Results

Financial Results Update

Corporate Governance Exemption

Regulatory Compliance

Management Change

Trading Window Closure

AGM Report Submission

Annual General Meeting

Management Change

Board Meeting Outcome

Board Meeting Outcome

Board Meeting Outcome

Compliance Report Submission

Certificate Submission

Exemption Notification

Material default announcement

Disclosure Submission

Disclosure Submission

Management Appointment

Management Change

Certificate Submission

Non-Applicability of Corpor...

Trading Window Closure

Resignation Announcement

Board Meeting Outcome

Trading Window Closure

Non-Applicability of Corpor...

SEBI Compliance Certificate

Confirmation of No Deviatio...

Financial Results Submission

Non-applicability of Regula...

Compliance Certificate Subm...

Trading Window Closure

Appointment of Company Secr...

Resignation of Company Secr...

External Links:

Data:

Vilin Bio Med Limited's suspension order has been revoked, allowing them to resume manufacturing Non-beta Lactam Tablets and Capsules, effective May 31, 2025, while other product sections remain suspended.

AI Assistant

Vilin Bio Med Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.